CT Lung Nodule Assessment
Assess lung nodules over time
CT Lung Nodule Assessment
Assess lung nodules over time
Enables review and analysis of thoracic CT images, providing segmentation, quantification and characterization of physician-indicated lung nodules in a single study, or over the course of several prefetched thoracic studies.
The application can be used in both diagnostic and screening evaluations, supporting Low Dose CT Lung Cancer Screening(1). Offers a Prediction Risk Calculator(2)(3) tool based on patient and nodule characteristics for estimation of the probability that the lung nodules detected on baseline screening low-dose CT are malignant. Discreate results sharing (4) enables automatic transfer of structural results between the Workspace and reporting solutions, reducing reporting time and optimizing AV reporting workflow.
Automatic lung and lobes segmentation
Auto-matches nodules across timepoints
Prediction Risk Calculator tool
Recommended products
- Incisive CT helps you meet some of your organization’s most pressing challenges. Philips Incisive CT offers intellect at every step, from acquisition through results, and across all fronts: financial, clinical and operational. Like never before, operator and design efficiencies come together for wise decisions from start to finish with an unprecedented Tube for Life guarantee¹. Now with the CT Smart Workflow, Incisive CT has further differentiated itself. CT Smart Workflow is an entirely new package of AI enabled tools that bring you the industry’s fastest AI reconstruction, automatic patient positioning and so much more to aid successful exams with fast results at low dose. From motion-free cardiac imaging to interventional procedures with confidence, CT Smart Workflow offers you advances that matter in your day-to-day imaging.
Disclaimer
(1) The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or professional medical society. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.
(2) Offered as separate commercial add-on.
(3) These functionalities may not be available in all territories. Please contact a Philips representative for more details.
(4) The integration of the solution is via IBE services or via customer home-grown solutions.